stockrow
Friday 6 November 2026
Export MBRX’s income statement to Excel — free account
Moleculin Biotech, Inc.
MBRX Healthcare Biotechnology
- EPS
- +95.1%
- Free cash flow
- −19.3%
Quarter to June 2026, against a year earlier
8.87
0.14
+1.60%
Follow MBRX
Alert me
Moleculin Biotech, Inc. (MBRX) P/E ratio
As of 5 November 2026, Moleculin Biotech, Inc. (MBRX) trades at a P/E ratio of 0.0×. Over the past ten years it has ranged from 0.0× (June 2026) to 0.2× (June 2026); the current reading is higher than 97% of that period. That is below the Biotechnology industry median of 10.3× and below the Healthcare sector median of 25.2×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 0.2×
Ten-year median
0.0×
Current reading's percentile
97
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| MTVA MetaVia Inc. compare | n/m |
| NKGN NKGen Biotech, Inc. compare | n/m |
| CMMB Chemomab Therapeutics Ltd. Sponsored ADR compare | n/m |
| CURX Curanex Pharmaceuticals Inc compare | n/m |
| LTRN Lantern Pharma Inc. compare | n/m |
| TOVX Theriva Biologics, Inc. compare | n/m |
| ICU SeaStar Medical Holding Corporation compare | n/m |
| ACTU Actuate Therapeutics, Inc. compare | n/m |
| MBRX Moleculin Biotech, Inc. | 0.0× |
| Biotechnology industry median | 10.3× |
| Healthcare sector median | 25.2× |
| Market median | 17.9× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)